<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordsOutput><serviceExecutionTime>344</serviceExecutionTime><Drug id="44658"><DrugName>filgrastim (amyotrophic lateral sclerosis), Neurovision</DrugName><DrugNamesKey><Name id="42754937">filgrastim</Name></DrugNamesKey><DrugSynonyms><Name><Value>filgrastim</Value><Types><Type>USAN</Type><Type>BAN</Type><Type>INN</Type></Types></Name><Name><Value>rhG-CSF</Value></Name><Name><Value>AX-200</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>G-CSF (protein recombinant/iv, stroke/ALS/PAO/PD/SCI), Sygnis</Value></Name><Name><Value>granulocyte colony stimulating factor (intravenous, peripheral arterial occlusive disease/spinal cord injury/stroke/Parkinsons disease), Axaron</Value></Name><Name><Value>granulocyte colony stimulating factor (stroke, ALS), Sygnis</Value></Name><Name><Value>filgrastim (stroke, ALS), Sygnis</Value></Name><Name><Value>filgrastim (amyotrophic lateral sclerosis), Neurovision</Value></Name></DrugSynonyms><CompanyOriginator id="29250">SYGNIS Bioscience GmbH &amp; Co KG</CompanyOriginator><CompaniesPrimary><Company id="1105804">Neurovision Pharma GmbH</Company></CompaniesPrimary><CompaniesSecondary><Company id="29250">SYGNIS Bioscience GmbH &amp; Co KG</Company></CompaniesSecondary><CrossReferences><SourceEntity id="44658" type="Drug"><TargetEntity id="342636" type="siDrug">Filgrastim</TargetEntity></SourceEntity><SourceEntity id="1105804" type="Company"><TargetEntity id="5044816533" type="organizationId">Neurovision Pharma GmbH</TargetEntity></SourceEntity><SourceEntity id="29250" type="Company"><TargetEntity id="4297575279" type="organizationId">Expedeon GmbH &amp; Co KG</TargetEntity></SourceEntity><SourceEntity id="1258" type="ciIndication"><TargetEntity id="10041552" type="MEDDRA"></TargetEntity><TargetEntity id="D013119" type="MeSH"></TargetEntity><TargetEntity id="90058" type="ORPHANET"></TargetEntity><TargetEntity id="-1980782964" type="omicsDisease"></TargetEntity><TargetEntity id="178" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1598" type="ciIndication"><TargetEntity id="10062585" type="MEDDRA"></TargetEntity></SourceEntity><SourceEntity id="212" type="ciIndication"><TargetEntity id="G12.2" type="ICD10"></TargetEntity><TargetEntity id="10028003" type="MEDDRA"></TargetEntity><TargetEntity id="D016472" type="MeSH"></TargetEntity><TargetEntity id="1290" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="255" type="ciIndication"><TargetEntity id="G20" type="ICD10"></TargetEntity><TargetEntity id="10061536" type="MEDDRA"></TargetEntity><TargetEntity id="D010300" type="MeSH"></TargetEntity><TargetEntity id="-342157116" type="omicsDisease"></TargetEntity><TargetEntity id="127" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="65" type="ciIndication"><TargetEntity id="D020521" type="MeSH"></TargetEntity><TargetEntity id="-1815339002" type="omicsDisease"></TargetEntity><TargetEntity id="93" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3151" type="Action"><TargetEntity id="1121" type="Mechanism">G-CSF Mimetics</TargetEntity><TargetEntity id="3384" type="Mechanism">G-CSF Receptor Agonists</TargetEntity></SourceEntity><SourceEntity id="PTGT-00800" type="ciTarget"><TargetEntity id="36485060414413" type="siTarget">Granulocyte colony-stimulating factor receptor</TargetEntity><TargetEntity id="276" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DR">Discovery</PhaseHighest><RegulatoryDesignations><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="212">Motor neurone disease</Indication></IndicationsPrimary><IndicationsSecondary><Indication id="1258">Spinal cord injury</Indication><Indication id="1598">Peripheral arterial occlusive disease</Indication><Indication id="255">Parkinsons disease</Indication><Indication id="65">Stroke</Indication></IndicationsSecondary><ActionsPrimary><Action id="3151">GCSF receptor agonist</Action></ActionsPrimary><ActionsSecondary><Action id="1615">Neuroprotectant</Action><Action id="270">Neuronal growth factor</Action><Action id="945">Vascular agent</Action></ActionsSecondary><Technologies><Technology id="85">Protein recombinant</Technology><Technology id="761">Biological therapeutic</Technology><Technology id="648">Intravenous formulation</Technology></Technologies><LastModificationDate>2019-05-31T08:55:00.000Z</LastModificationDate><ChangeDateLast>2016-10-27T00:00:00.000Z</ChangeDateLast><AddedDate>2003-04-16T14:41:23.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1105804" linkType="Company"&gt;Neurovision Pharma&lt;/ulink&gt;, presumably under license from &lt;ulink linkID="27417" linkType="Company"&gt;SYGNIS&lt;/ulink&gt;, is investigating &lt;ulink url="filgrastim"&gt;filgrastim&lt;/ulink&gt;, recombinant human granulocyte-colony stimulating factor (rhG-CSF), for the potential treatment of amyotrophic lateral sclerosis (ALS) [&lt;ulink linkID="1633481" linkType="Reference"&gt;1633481&lt;/ulink&gt;]. In April 2015, clinical data were presented [&lt;ulink linkID="1651687" linkType="Reference"&gt;1651687&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;ulink linkID="29250" linkType="Company"&gt;SYGNIS&lt;/ulink&gt; (previously Axaron) was developing filgrastim (as AX-200) as a  neuroprotectant for the potential iv treatment  of ALS, spinal cord injury (SCI), peripheral arterial occlusive disease (PAO) and was investigating the drug for the potential treatment of Parkinson's disease (PD)  [&lt;ulink linkID="494474" linkType="reference"&gt;494474&lt;/ulink&gt;], [&lt;ulink linkID="634324" linkType="Reference"&gt;634324&lt;/ulink&gt;], [&lt;ulink linkID="854668" linkType="Reference"&gt;854668&lt;/ulink&gt;], [&lt;ulink linkID="1178174" linkType="Reference"&gt;1178174&lt;/ulink&gt;], [&lt;ulink linkID="1254274" linkType="Reference"&gt;1254274&lt;/ulink&gt;]. In March 2011, in vivo data had been reported for PD [&lt;ulink linkID="1178174" linkType="Reference"&gt;1178174&lt;/ulink&gt;]. In January 2012, the drug was listed as being in phase I development for ALS, SCI and PAO  [&lt;ulink linkID="1254274" linkType="Reference"&gt;1254274&lt;/ulink&gt;]. In November 2011, the company was seeking partners for the clinical development for stroke, ALS and SCI [&lt;ulink linkID="1254276" linkType="Reference"&gt;1254276&lt;/ulink&gt;]. However, in July 2012, the company reported that it completely wrote off the project, as commercialization intention of the drug was ruled out [&lt;ulink linkID="1310943" linkType="Reference"&gt;1310943&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The drug was previously under development for the potential treatment of stroke, and in   November 2011, the company was seeking partners for the clinical development for stroke   [&lt;ulink linkID="486095" linkType="reference"&gt;486095&lt;/ulink&gt;], [&lt;ulink linkID="1254276" linkType="Reference"&gt;1254276&lt;/ulink&gt;]; however, in February 2012, the company announced it would cease development for this indication after a phase II study missed its endpoints [&lt;ulink linkID="1249464" linkType="Reference"&gt;1249464&lt;/ulink&gt;], [&lt;ulink linkID="1262681" linkType="Reference"&gt;1262681&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;SYGNIS was also investigating  an &lt;ulink linkID="74445" linkType="Drug"&gt;adenovirus-associated vector (AAV)-delivered   G-CSF gene therapy&lt;/ulink&gt;  for the potential treatment of    ALS.&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;In January 2015, the FDA granted filgrastim Orphan designation for the treatment of ALS [&lt;ulink linkID="1633481" linkType="Reference"&gt;1633481&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;In February 2008, the EMEA's COMP adopted a positive opinion on granting Orphan Drug status to AX-200 for ALS [&lt;ulink linkID="875826" linkType="Reference"&gt;875826&lt;/ulink&gt;], [&lt;ulink linkID="877058" linkType="Reference"&gt;877058&lt;/ulink&gt;].; in April 2008, the EC granted AX-200 Orphan Drug status for ALS [&lt;ulink linkID="899467" linkType="Reference"&gt;899467&lt;/ulink&gt;].  In September 2008, the EMEA's COMP adopted a positive opinion on granting the drug Orphan Drug status for SCI [&lt;ulink linkID="944457" linkType="Reference"&gt;944457&lt;/ulink&gt;]; in November 2008, the EC awarded Orphan status  for SCI [&lt;ulink linkID="963196" linkType="Reference"&gt;963196&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Stroke&lt;/subtitle&gt;In November 2008, a European phase II trial for stroke (AXIS-II) was expected to begin in the first half of 2009 [&lt;ulink linkID="967092" linkType="Reference"&gt;967092&lt;/ulink&gt;], [&lt;ulink linkID="976535" linkType="Reference"&gt;976535&lt;/ulink&gt;]. In January 2009, the company reported that the German regulatory authority (BfArM) had approved the technical and preclinical documentation of the phase II trial, and preparations for the study had been completed. The 18-month, European, multicenter study was to enroll 350 patients. Patient enrollment was planned for the first half of 2009 [&lt;ulink linkID="976535" linkType="Reference"&gt;976535&lt;/ulink&gt;]. In February 2009, it was reported at the 2009 International Stroke Conference in San Diego, CA, that the trial was to enroll 400 patients and was expected to begin in the next 2 months [&lt;ulink linkID="988243" linkType="Reference"&gt;988243&lt;/ulink&gt;]. In May 2009, a phase II, multinational, randomized, double-blind, placebo-controlled, 350-patient trial (&lt;ulink linkID="58271" linkType="Protocol"&gt;NCT00927836&lt;/ulink&gt;, AXIS 2, AX200-101, EudraCT- 2008-006444-19) for acute ischemic stroke began. AX-200 would be given as a 3-day infusion to patients enrolled up to 9 h after an ischemic stroke. The primary endpoint was patient outcome, and the secondary endpoints included clinical scales for functional ability, safety, and changes in infarct size. At that time, enrollment was to take 18 months and initial data were expected 6 months later. The study was expected to complete by June 2011 [&lt;ulink linkID="1006138" linkType="Reference"&gt;1006138&lt;/ulink&gt;], [&lt;ulink linkID="1178180" linkType="Reference"&gt;1178180&lt;/ulink&gt;]. In February 2010, SYGNIS reported that enrollment was progressing slower than expected [&lt;ulink linkID="1074742" linkType="Reference"&gt;1074742&lt;/ulink&gt;]. In June 2010, initial results were expected in mid-2011 [&lt;ulink linkID="1111324" linkType="Reference"&gt;1111324&lt;/ulink&gt;]. In August 2010, the trial's data safety monitoring board (DSMB) advised the study continue without changes [&lt;ulink linkID="1123946" linkType="Reference"&gt;1123946&lt;/ulink&gt;]. By November 2010, a modification to the study protocol had accelerated enrollment. At that time, top-line data were expected in the second half of 2011 [&lt;ulink linkID="1147235" linkType="Reference"&gt;1147235&lt;/ulink&gt;]. In December 2010, the independent DSMB approved the unmodified continuation of the study [&lt;ulink linkID="1157529" linkType="Reference"&gt;1157529&lt;/ulink&gt;]. In March 2011, the independent DSMB held its final interim review  and recommended  the unmodified continuation of the trial [&lt;ulink linkID="1178439" linkType="Reference"&gt;1178439&lt;/ulink&gt;]. By June 2011,  topline results were expected by the end of 2011 [&lt;ulink linkID="1204096" linkType="Reference"&gt;1204096&lt;/ulink&gt;]. Enrollment of 328 patients was complete in August 2011 [&lt;ulink linkID="1213614" linkType="Reference"&gt;1213614&lt;/ulink&gt;]. In November 2011, treatment of patients was completed [&lt;ulink linkID="1236373" linkType="Reference"&gt;1236373&lt;/ulink&gt;]. In December 2011, preliminary results reported that the study missed its endpoints.  The study showed  no clinical improvement and  any statistically significant difference in the primary endpoint of  functional improvement, using the modified Rankin Scale and also in the secondary endpoint of improvement using the National Institutes of Health Stroke Scale,   relative to placebo-treated patients. At that time, full data were expected  in the first quarter of  2012 [&lt;ulink linkID="1249464" linkType="Reference"&gt;1249464&lt;/ulink&gt;]. In February 2012, data were presented at the American Stroke Association's International Stroke Conference 2012 in New Orleans, LA. After 90 days of treatment, patients receiving AX-200 or  placebo both scored  3 on the 0-6 modified Rankin Scale.  The National Institutes of Health Stroke Scale also demonstrated an insignificant difference between the drug and placebo, of  less than half a point (8.88 for AX-200 versus 8.45 for placebo) [&lt;ulink linkID="1259985" linkType="Reference"&gt;1259985&lt;/ulink&gt;]. Later that month, the company announced it would cease development of AX-200 for stroke [&lt;ulink linkID="1262681" linkType="Reference"&gt;1262681&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2007, SYGNIS was planning a phase IIb trial [&lt;ulink linkID="814795" linkType="Reference"&gt;814795&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2005, information on the AXIS-I trial were presented at the 35th SFN meeting in Washington DC. This phase IIa, multicenter, randomized, double-blind, placebo-controlled, dose-escalating trial (&lt;ulink linkID="5944" linkType="Protocol"&gt;NCT00132470&lt;/ulink&gt;; AX200_P2A_1) was planned  in stroke patients at ten centers in Germany [&lt;ulink linkID="1178189" linkType="Reference"&gt;1178189&lt;/ulink&gt;], [&lt;ulink linkID="634598" linkType="Reference"&gt;634598&lt;/ulink&gt;]. The  trial was scheduled to complete in early 2006  [&lt;ulink linkID="634598" linkType="Reference"&gt;634598&lt;/ulink&gt;]. Of the 44 patients enrolled,  14 received placebo and 30 received four doses of AX-200 during a 3-day treatment regimen comprising a 20 min short infusion of one third of the total dose on day 1, followed by a 3-day continuous iv infusion. The primary endpoint was thromboembolic complications through discharge on day 4 and secondary endpoints was severe infections attributed to the agent [&lt;ulink linkID="634598" linkType="Reference"&gt;634598&lt;/ulink&gt;], [&lt;ulink linkID="830973" linkType="Reference"&gt;830973&lt;/ulink&gt;].  In July 2007, results were reported. AX-200 was safe and, although the trial was not designed to show efficacy, the data suggested that the drug was effective.  By July 2007, a phase IIa trial in stroke patients had been completed [&lt;ulink linkID="814795" linkType="Reference"&gt;814795&lt;/ulink&gt;], [&lt;ulink linkID="1042330" linkType="Reference"&gt;1042330&lt;/ulink&gt;]. In September 2007, in-depth analysis of the data confirmed the safety of the drug, and that both primary and secondary endpoints were met [&lt;ulink linkID="830973" linkType="Reference"&gt;830973&lt;/ulink&gt;], [&lt;ulink linkID="1042326" linkType="Reference"&gt;1042326&lt;/ulink&gt;]. In February 2009, these data were presented at the 2009 International Stroke Conference in San Diego, CA [&lt;ulink linkID="988243" linkType="Reference"&gt;988243&lt;/ulink&gt;]. By March 2011,  a dose related increase in white blood cell count had been observed [&lt;ulink linkID="1178174" linkType="Reference"&gt;1178174&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2003, phase II trials  were expected to commence towards the end of 2003 [&lt;ulink linkID="486095" linkType="reference"&gt;486095&lt;/ulink&gt;], [&lt;ulink linkID="485992" linkType="reference"&gt;485992&lt;/ulink&gt;]. By January 2004, the compound was expected to commence phase II trials in the second quarter of 2004 [&lt;ulink linkID="519380" linkType="reference"&gt;519380&lt;/ulink&gt;]. By November 2005, an international phase IIb trial was planned for the end of 2006 [&lt;ulink linkID="634598" linkType="Reference"&gt;634598&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2008, a clinical study in 36 healthy volunteers showed that the material to be used for a planned phase II trial was safe and well-tolerated within the decided dose range [&lt;ulink linkID="976535" linkType="Reference"&gt;976535&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;SCI and ALS&lt;/subtitle&gt;In April 2015, clinical data were presented from a clinical study in 23 patients with ALS at the 67th AAN Annual Meeting in Washington DC. Patients received G-CSF (5 to 10 microg/kg body weight, sc) plus standard treatment including &lt;ulink linkID="5859" linkType="Drug"&gt;riluzole&lt;/ulink&gt;. Overall, compliance was excellent. Treatment was well tolerated with some known side effects of mild bone pain in all patients [&lt;ulink linkID="1651687" linkType="Reference"&gt;1651687&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2008, the company was planning clinical trials for  SCI [&lt;ulink linkID="944457" linkType="Reference"&gt;944457&lt;/ulink&gt;]. By December 2009,  the company planned to begin phase I development  for ALS and SCI in 2010 [&lt;ulink linkID="1178174" linkType="Reference"&gt;1178174&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;&lt;subtitle&gt;Stroke&lt;/subtitle&gt;In November 2005, preclinical data on AX-200 for the potential treatment of stroke were presented at the 35th SFN meeting in Washington DC, describing the efficacy of the drug in animal models. In a transient middle cerebral artery occlusion (MCAO) rat model of stroke, AX-200 (60 microg/kg, 20 min, iv) demonstrated efficacy (reduction in infarct volume) when administered at either 2 or 4 h after onset of ischemia. In the combined CCA/distal MCA rat model, the same dose of AX-200 reduced infarct volume when administered 1 h after onset of ischemia. In vitro studies revealed that AX-200 and its receptor are expressed in neurons in the human brain, including hippocampal and pyramidal neurons. AX-200 (50 ng/ml) protected human SH-SY-5Y neuroblastoma cells against apoptotic stimuli. Immunohistochemistry data demonstrated that the G-CSF receptor is neuronally expressed after onset of stroke in humans [&lt;ulink linkID="634598" linkType="Reference"&gt;634598&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2003, preclinical studies were ongoing. AX-200 had demonstrated multiple modes of action and was capable of protecting brain cells from damage occurring during the acute phase of stroke. It also improved the functional performance thereafter [&lt;ulink linkID="486095" linkType="reference"&gt;486095&lt;/ulink&gt;].   &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;ALS&lt;/subtitle&gt;By March 2011,  in vivo data  had shown  that AX-200 counteracts neuronal cell death by prolonging the cell survival,   maintenance of muscular strength for a longer time and reducing muscle degeneration. Proof-of–concept had been established for ALS [&lt;ulink linkID="1178174" linkType="Reference"&gt;1178174&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2005, preclinical data on AX-200  for the  potential treatment of ALS were presented at the 35th SFN conference in Washington DC. AX-200 protected the motoneuron/neuroblastoma cell line NSC-34 from apoptotic cell death and activated the Akt kinase pathway. In the  SOD1 (G93A) transgenic  mouse model of  ALS,  AX-200 (30 microg/kg/day, sc), administered continuously for 8 weeks via an osmotic pump, significantly improved the overall motor performance of the transgenic mice by approximately 40%. It delayed the onset of symptoms in, functional impairment of, and prolonged overall survival of the transgenic mice by 10-15%, 15-18%, and 7-10%, respectively [&lt;ulink linkID="634324" linkType="Reference"&gt;634324&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Spinal cord injury&lt;/subtitle&gt;By March 2011, proof-of-concept  had been established in in vivo models of   SCI [&lt;ulink linkID="1178174" linkType="Reference"&gt;1178174&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By November 2008, preclinical trials had demonstrated AX-200's ability to counteract neuronal cell death and to support neuronal regeneration which facilitates functional recovery after spinal cord injury [&lt;ulink linkID="963196" linkType="Reference"&gt;963196&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Parkinsons disease&lt;/subtitle&gt;By March 2011, the drug had shown convincing therapeutic effects in in vivo models of Parkinson's disease [&lt;ulink linkID="1178174" linkType="Reference"&gt;1178174&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In December 2008, SYGNIS announced that the USPTO had issued a patent in the &lt;ulink linkID="PA2903517" linkType="Patent"&gt;WO-2004058287&lt;/ulink&gt; family, which covered the use of GMCSF for treating stroke [&lt;ulink linkID="968666" linkType="Reference"&gt;968666&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By December 2008, SYGNIS had exclusively licensed global rights to  a patent application for AX-200 from an undisclosed company [&lt;ulink linkID="968666" linkType="Reference"&gt;968666&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2007, &lt;ulink linkID="29387" linkType="Company"&gt;Dr. Reddy's Laboratories&lt;/ulink&gt; agreed to supply SYGNIS Pharma with  AX-200 [&lt;ulink linkID="854668" linkType="Reference"&gt;854668&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1105804">Neurovision Pharma GmbH</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="212">Motor neurone disease</Indication><StatusDate>2015-01-27T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1105804">Neurovision Pharma GmbH</Company><Country id="DE">Germany</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="212">Motor neurone disease</Indication><StatusDate>2015-01-27T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29250">SYGNIS Bioscience GmbH &amp; Co KG</Company><Country id="DE">Germany</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="255">Parkinsons disease</Indication><StatusDate>2012-07-25T00:00:00.000Z</StatusDate><Source id="1310943" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29250">SYGNIS Bioscience GmbH &amp; Co KG</Company><Country id="DE">Germany</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="1598">Peripheral arterial occlusive disease</Indication><StatusDate>2012-07-25T00:00:00.000Z</StatusDate><Source id="1310943" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29250">SYGNIS Bioscience GmbH &amp; Co KG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="65">Stroke</Indication><StatusDate>2012-02-14T00:00:00.000Z</StatusDate><Source id="1262681" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29250">SYGNIS Bioscience GmbH &amp; Co KG</Company><Country id="DE">Germany</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="1258">Spinal cord injury</Indication><StatusDate>2012-07-25T00:00:00.000Z</StatusDate><Source id="1310943" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29250">SYGNIS Bioscience GmbH &amp; Co KG</Company><Country id="DE">Germany</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="212">Motor neurone disease</Indication><StatusDate>2015-01-27T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="29250">SYGNIS Bioscience GmbH &amp; Co KG</Company><Country id="DE">Germany</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1598">Peripheral arterial occlusive disease</Indication><StatusDate>2011-03-22T00:00:00.000Z</StatusDate><Source id="1178174" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29250">SYGNIS Bioscience GmbH &amp; Co KG</Company><Country id="DE">Germany</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1258">Spinal cord injury</Indication><StatusDate>2008-09-18T00:00:00.000Z</StatusDate><Source id="944457" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29250">SYGNIS Bioscience GmbH &amp; Co KG</Company><Country id="DE">Germany</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="212">Motor neurone disease</Indication><StatusDate>2005-11-16T00:00:00.000Z</StatusDate><Source id="634324" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29250">SYGNIS Bioscience GmbH &amp; Co KG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="65">Stroke</Indication><StatusDate>2004-10-01T00:00:00.000Z</StatusDate><Source id="635699" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29250">SYGNIS Bioscience GmbH &amp; Co KG</Company><Country id="DE">Germany</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="255">Parkinsons disease</Indication><StatusDate>2011-03-22T00:00:00.000Z</StatusDate><Source id="1178174" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29250">SYGNIS Bioscience GmbH &amp; Co KG</Company><Country id="DE">Germany</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1258">Spinal cord injury</Indication><StatusDate>2011-10-24T00:00:00.000Z</StatusDate><Source id="1254276" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29250">SYGNIS Bioscience GmbH &amp; Co KG</Company><Country id="DE">Germany</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1598">Peripheral arterial occlusive disease</Indication><StatusDate>2011-10-24T00:00:00.000Z</StatusDate><Source id="1254276" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29250">SYGNIS Bioscience GmbH &amp; Co KG</Company><Country id="DE">Germany</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="212">Motor neurone disease</Indication><StatusDate>2011-10-24T00:00:00.000Z</StatusDate><Source id="1254276" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29250">SYGNIS Bioscience GmbH &amp; Co KG</Company><Country id="DE">Germany</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="212">Motor neurone disease</Indication><StatusDate>2012-07-25T00:00:00.000Z</StatusDate><Source id="1310943" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29250">SYGNIS Bioscience GmbH &amp; Co KG</Company><Country id="DE">Germany</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="65">Stroke</Indication><StatusDate>2003-04-16T00:00:00.000Z</StatusDate><Source id="486095" type="CORPORATE"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1105804">Neurovision Pharma GmbH</OwnerCompany><Country id="EU">EU</Country><Indication id="212">Motor neurone disease</Indication><AwardedIndication>Treatment of amyotrophic lateral sclerosis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="5">Transfer of Ownership</DesignationApplicationStatus><MileStoneDate>2015-02-28T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1105804">Neurovision Pharma GmbH</OwnerCompany><Country id="EU">EU</Country><Indication id="1258">Spinal cord injury</Indication><AwardedIndication>Treatment of spinal cord injury</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="5">Transfer of Ownership</DesignationApplicationStatus><MileStoneDate>2015-02-28T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1105804">Neurovision Pharma GmbH</OwnerCompany><Country id="US">US</Country><Indication id="212">Motor neurone disease</Indication><AwardedIndication>Treatment of amyotrophic lateral sclerosis (ALS)</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2015-01-27T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1105804">Neurovision Pharma GmbH</OwnerCompany><Country id="EU">EU</Country><Indication id="1258">Spinal cord injury</Indication><AwardedIndication>Treatment of spinal cord injury</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="5">Transfer of Ownership</DesignationApplicationStatus><MileStoneDate>2014-04-30T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1105804">Neurovision Pharma GmbH</OwnerCompany><Country id="EU">EU</Country><Indication id="212">Motor neurone disease</Indication><AwardedIndication>Treatment of amyotrophic lateral sclerosis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="5">Transfer of Ownership</DesignationApplicationStatus><MileStoneDate>2014-04-30T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1105804">Neurovision Pharma GmbH</OwnerCompany><Country id="EU">EU</Country><Indication id="1258">Spinal cord injury</Indication><AwardedIndication>Treatment of spinal cord injury</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2008-11-07T00:00:00.000Z</MileStoneDate><Source id="963196" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1105804">Neurovision Pharma GmbH</OwnerCompany><Country id="EU">EU</Country><Indication id="1258">Spinal cord injury</Indication><AwardedIndication>Treatment of spinal cord injury</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate>2008-09-10T00:00:00.000Z</MileStoneDate><Source id="944457" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1105804">Neurovision Pharma GmbH</OwnerCompany><Country id="EU">EU</Country><Indication id="212">Motor neurone disease</Indication><AwardedIndication>Treatment of amyotrophic lateral sclerosis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2008-04-01T00:00:00.000Z</MileStoneDate><Source id="899467" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1105804">Neurovision Pharma GmbH</OwnerCompany><Country id="EU">EU</Country><Indication id="212">Motor neurone disease</Indication><AwardedIndication>Treatment of amyotrophic lateral sclerosis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate>2008-02-06T00:00:00.000Z</MileStoneDate><Source id="877058" type="PR"/></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-00800"><Name>GCSF receptor</Name><SwissprotNumbers><Swissprot>P40223</Swissprot><Swissprot>Q99062</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1105804">Neurovision Pharma GmbH</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="27417">SYGNIS AG</Company><CountAsPrincipalActive>2</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>2</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>3</CountTotal></Company><Company><Company id="29387">Dr Reddy's Laboratories Ltd</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="11">Patent - Exclusive Rights</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="6">Drug - Manufacturing/Supply</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="110852" title="Dr. Reddy's to supply Sygnis with AX-200"/><Deal id="118502" title="SYGNIS Pharma to use patent application for AX-200 neuroprotectant from undisclosed partner"/><Deal id="153109" title="Neurovision Pharma to develop SYGNIS Bioscience's filgrastim   "/></Deals><PatentFamilies><PatentFamily id="2123711" number="WO-2004058287" title="Methods of treating neurological conditions with hematopoeitic growth factors"/><PatentFamily id="2355519" number="WO-2009037191" title="Use of G-CSF for the treatment of stroke"/><PatentFamily id="3264161" number="EP-03050570" title="Pharmaceutical composition consisting of a combination of G-CSF with GM-CSF"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Neurovision Pharma GmbH" id="1105804"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Individual" id="21144"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="SYGNIS AG" id="27417"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Heidelberg" id="28348"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></Drug></drugRecordsOutput>